

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**IN THE CLAIMS:**

1. (Original) An isolated compound which modulates G-CSF-induced cellular responses wherein the compound inhibits or activates G-CSF activity or levels *via* a SOCS molecule.
2. (Original) The compound of Claim 1 wherein the compound up-regulates the activity or levels of SOCS-3.
3. (Original) The compound of Claim 1 wherein the compound down-regulates the activity or levels of SOCS-3.
4. (Currently Amended) The compound of ~~any one of Claims 1 to 3~~ claim 1 wherein the compound is a nucleic acid molecule.
5. (Original) The compound of Claim 4 wherein the nucleic acid molecule is an oligonucleotide.
6. (Currently Amended) The compound of Claim 4 [[or 5]] wherein the nucleic acid molecule is mRNA, RNAi, siRNA or DNA or a complex containing same.
7. (Original) The compound of Claim 6 wherein the nucleic acid molecule is a sense or antisense oligonucleotide.

8. (Currently Amended) The compound of ~~any one of Claims 1 to 3~~ claim 1 wherein the compound is a proteinaceous molecule.
9. (Currently Amended) The compound of ~~any one of Claims 1 to 3~~ claim 1 wherein the compound is a non-protein chemical.
10. (Currently Amended) A pharmaceutical composition comprising ~~a component of any one of Claims 1 to 11~~ an isolated compound which modulates G-CSF-induced cellular responses wherein the compound inhibits or activates G-CSF activity or levels *via* a SOCS molecule and one or more pharmaceutically acceptable carriers and/or diluents.
11. (Original) The pharmaceutical composition of Claim 10 wherein the composition is a nucleic acid molecule.
12. (Original) The pharmaceutical composition of Claim 11 wherein the composition is a gene therapy composition.
13. (Currently Amended) A method for modulating G-CSF-induced cellular responses in a mammal, said method comprising administering to said mammal an effective amount of ~~a compound of any one of Claims 1 to 9~~ an isolated compound which modulates G-CSF-induced cellular responses wherein the compound inhibits or activates G-CSF activity or levels *via* a SOCS molecule or a pharmaceutical composition of Claim 10 or 11 or 12, comprising said isolated compound and one or more pharmaceutically acceptable carriers and/or diluents.
14. (Original) The method of Claim 13 wherein the mammal is a human.
15. (Currently Amended) The method of Claim 13 [[or 14]] wherein the compound inhibits or elevates levels of SOCS-3.
16. (Original) An animal model useful for screening for compounds which modulate G-

CSF-induced cellular responses, said model comprising a genetically modified animal which comprises cells which produce elevated or reduced levels of SOCS-3.

17. (Original) The animal model of Claim 16 wherein the animal is a non-human primate, lower primate, mouse, rat, rabbit, sheep, goat or pig.